Abstract
Epoxyeicosanoids, including the epoxyeicosatrienoic acids, are signaling molecules which appear to help ameliorate the effects of a wide variety of pathological conditions. The enzyme soluble epoxide hydrolase (sEH) metabolizes these molecules by converting them to their corresponding vicinal diols. Inhibition of sEH either by knockout or chemical inhibitors increases epoxyeicosanoid levels in vivo and provides significant organ protection in models of brain, cardiac, and renal injury. sEH also appears to be involved in modulating inflammation, pain pathways, pulmonary function, hypertension, and diabetes. Potent sEH inhibitors have been developed in academic, pharmaceutical, and biotech laboratories and described in the patent and scientific literature. Most of the inhibitor scaffolds employ a urea or amide which functions as an active-site transition state mimic. Arete Therapeutics compound AR9281 successfully completed phase Ia and Ib studies. A phase IIa proof of concept trial for treatment of impaired glucose tolerance has been completed, but the results are not yet reported.
Keywords: AR9281, BTP2, EPHX2, epoxyeicosatrienoic acid, eicosanoids, sEH, soluble epoxide hydrolase, Multiple Pathologic Conditions, Epoxyeicosanoids, ameliorate, vicinal diols, homodimeric bifunctional enzyme, linoleic acid, pyrophosphates, farnesyl, geranyl-geranyl, cytosol,, endothelial-derived hyperpolarizing factor, transient ischemic attack (TIA), MCAO (Middle Cerebral, HAMMOCK LABORATORY PHARMACOPHORE MODEL, secondary pharmacophore, am-ide, ketone, alcohol, carbamate, benzoheterocycle, alkyl spacers, adamantane piperidinyl ureas, piperidinyl ureas, BOEHRINGER INGELHEIM, HOFFMAN LA ROCHE, TAISHO, MERCK
Current Medicinal Chemistry
Title: Soluble Epoxide Hydrolase Inhibitors and their Potential for Treatment of Multiple Pathologic Conditions
Volume: 18 Issue: 4
Author(s): R. H. Ingraham, R. D. Gless and H. Y. Lo
Affiliation:
Keywords: AR9281, BTP2, EPHX2, epoxyeicosatrienoic acid, eicosanoids, sEH, soluble epoxide hydrolase, Multiple Pathologic Conditions, Epoxyeicosanoids, ameliorate, vicinal diols, homodimeric bifunctional enzyme, linoleic acid, pyrophosphates, farnesyl, geranyl-geranyl, cytosol,, endothelial-derived hyperpolarizing factor, transient ischemic attack (TIA), MCAO (Middle Cerebral, HAMMOCK LABORATORY PHARMACOPHORE MODEL, secondary pharmacophore, am-ide, ketone, alcohol, carbamate, benzoheterocycle, alkyl spacers, adamantane piperidinyl ureas, piperidinyl ureas, BOEHRINGER INGELHEIM, HOFFMAN LA ROCHE, TAISHO, MERCK
Abstract: Epoxyeicosanoids, including the epoxyeicosatrienoic acids, are signaling molecules which appear to help ameliorate the effects of a wide variety of pathological conditions. The enzyme soluble epoxide hydrolase (sEH) metabolizes these molecules by converting them to their corresponding vicinal diols. Inhibition of sEH either by knockout or chemical inhibitors increases epoxyeicosanoid levels in vivo and provides significant organ protection in models of brain, cardiac, and renal injury. sEH also appears to be involved in modulating inflammation, pain pathways, pulmonary function, hypertension, and diabetes. Potent sEH inhibitors have been developed in academic, pharmaceutical, and biotech laboratories and described in the patent and scientific literature. Most of the inhibitor scaffolds employ a urea or amide which functions as an active-site transition state mimic. Arete Therapeutics compound AR9281 successfully completed phase Ia and Ib studies. A phase IIa proof of concept trial for treatment of impaired glucose tolerance has been completed, but the results are not yet reported.
Export Options
About this article
Cite this article as:
H. Ingraham R., D. Gless R. and Y. Lo H., Soluble Epoxide Hydrolase Inhibitors and their Potential for Treatment of Multiple Pathologic Conditions, Current Medicinal Chemistry 2011; 18 (4) . https://dx.doi.org/10.2174/092986711794480212
DOI https://dx.doi.org/10.2174/092986711794480212 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Effects of Highly Active Antiretroviral Therapy on Albuminuria in HIV-infected Persons
Infectious Disorders - Drug Targets Sinus Node If Channel Inhibition – A New Therapeutic Approach to Heart Rate Lowering
Current Drug Therapy Expeditious and Green Synthesis of 2,3-Dihydroquinazolin-4(1H)-ones Catalyzed by Nano-MgO
Letters in Organic Chemistry A Green and Efficient One-pot Synthesis of 1,2,3-Trisubstituted Pyrroles via Iodine-catalyzed Tandem Reaction
Letters in Organic Chemistry Anti-Oxidative Polyphenolic Compounds of Cocoa
Current Pharmaceutical Biotechnology Treatment of Periodontitis for the Prevention of Endothelial Dysfunction: A Narrative Review
Current Vascular Pharmacology Fish Hydrolysates: A Regulatory Perspective of Bioactive Peptides
Protein & Peptide Letters Subject Index To Volume 4
Current HIV Research Blood Pressure Variability/Dipper/Non-dipper in Hypertension and Diabetes
Current Hypertension Reviews 25 Hydroxyvitamin D Levels are Negatively and Independently Associated with Fat Mass in a Cohort of Healthy Overweight and Obese Subjects
Endocrine, Metabolic & Immune Disorders - Drug Targets Histological Alterations in the Testicular Tissue Induced by Sildenafil Overdoses
Drug Metabolism Letters Heat Shock Proteins Protect Against Ischemia and Inflammation Through Multiple Mechanisms
Inflammation & Allergy - Drug Targets (Discontinued) Interaction of Cyclosporine A and the Renin-Angiotensin System New Perspectives
Current Drug Metabolism Smoking and Eye Pathologies. A Systemic Review. Part II. Retina Diseases, Uveitis, Optic Neuropathies, Thyroid-Associated Orbitopathy
Current Pharmaceutical Design Polypharmacy in Cardiovascular Medicine: Problems and Promises!
Cardiovascular & Hematological Agents in Medicinal Chemistry Ethnicity and Drug Therapy for Hypertension
Current Pharmaceutical Design G Protein-Coupled Receptor Kinase 2 - a Feedback Regulator of Gq Pathway Signalling
Current Drug Targets - Immune, Endocrine & Metabolic Disorders PDE5 Inhibitors in Non-Urological Conditions
Current Pharmaceutical Design Exercise as a platform for pharmacotherapy development in cardiac diseases
Current Pharmaceutical Design Editorial (Thematic Issue: Understanding the Role of Heteroreceptor Complexes in the Central Nervous System)
Current Protein & Peptide Science